Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg;~2. for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;~3. available for all the visits scheduled in the study;~4. in good health as determined by medical history, physical examination and clinical judgment of the investigator.~Exclusion Criteria:~1. History of any meningococcal vaccine administration;~2. Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell), Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), Pneumococcal, MMR or varicella antigens;~3. Previous ascertained or suspected disease caused by N. meningitidis;~4. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis;~5. History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;~6. Significant acute or chronic infection within the previous 7 days or body temperature higher or equal to 38C degrees within the previous day;~7. Antibiotics within 6 days prior to enrollment;~8. Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, insulin dependent diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);~9. Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids since birth;~10. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation;~11. Receipt of, or intent to immunize with any other vaccine(s) (with the exception of rotavirus vaccine, influenza vaccine and second HepB vaccine), within 28 days prior and throughout the study period. Furthermore, subjects must have received HepB vaccine preferably at 0, 1 month of age, with the second dose at least 14 days prior to study vaccination. Influenza vaccine should be administered at least 14 days before or 14 days after study vaccination; Rotavirus vaccine may be administered during the study as per local practice.~12. Participation in another clinical trial since birth or planned for during study;~13. Family members and household members of research staff;~14. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- Bexsero + Routine Group (Type: EXPERIMENTAL): Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
- Routine Group (Type: ACTIVE_COMPARATOR): Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).